{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:15:28Z","timestamp":1767849328311,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,2]],"date-time":"2017-11-02T00:00:00Z","timestamp":1509580800000},"content-version":"vor","delay-in-days":732,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30 DK027651"],"award-info":[{"award-number":["P30 DK027651"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006501","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["CFFT KONSTA09Y0"],"award-info":[{"award-number":["CFFT KONSTA09Y0"]}],"id":[{"id":"10.13039\/100006501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","cysticfibrosisjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.jcf.2015.02.007","type":"journal-article","created":{"date-parts":[[2015,3,5]],"date-time":"2015-03-05T20:15:25Z","timestamp":1425586525000},"page":"763-769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5727-8164","authenticated-orcid":false,"given":"Donald R.","family":"VanDevanter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Pasta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Konstan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jcf.2015.02.007_bb0005","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jpeds.2005.10.019","article-title":"Cystic fibrosis pulmonary exacerbations","volume":"148","author":"Ferkol","year":"2006","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.jcf.2015.02.007_bb0010","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/thx.2006.060889","article-title":"Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis","volume":"62","author":"Goss","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2015.02.007_bb0015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jpeds.2007.03.006","article-title":"Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis","volume":"151","author":"Konstan","year":"2007","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.jcf.2015.02.007_bb0020","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.rmed.2008.09.024","article-title":"Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis","volume":"103","author":"Amadori","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.jcf.2015.02.007_bb0025","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/ppul.21311","article-title":"Pulmonary outcome prediction (POP) tools for cystic fibrosis patients","volume":"45","author":"VanDevanter","year":"2010","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"10.1016\/j.jcf.2015.02.007_bb0030","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/thx.2011.161117","article-title":"Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis","volume":"66","author":"de Boer","year":"2011","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.jcf.2015.02.007_bb0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1183\/09031936.00159111","article-title":"Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis","volume":"40","author":"Waters","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2015.02.007_bb0040","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1542\/peds.103.6.e72","article-title":"The cost of medical care for patients with cystic fibrosis in a health maintenance organization","volume":"103","author":"Lieu","year":"1999","journal-title":"Pediatrics"},{"key":"10.1016\/j.jcf.2015.02.007_bb0045","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1378\/chest.121.1.64","article-title":"Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis","volume":"121","author":"Britto","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2015.02.007_bb0050","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/aje\/153.4.345","article-title":"Predictive 5-year survivorship model of cystic fibrosis","volume":"153","author":"Liou","year":"2001","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jcf.2015.02.007_bb0055","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1164\/rccm.200202-087OC","article-title":"Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality","volume":"166","author":"Mayer-Hamblett","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jcf.2015.02.007_bb0060","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0022-3476(99)70197-6","article-title":"Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis","volume":"134","author":"Smith","year":"1999","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.jcf.2015.02.007_bb0065","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4155\/cli.11.174","article-title":"Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease","volume":"2","author":"VanDevanter","year":"2012","journal-title":"Clin Investig"},{"key":"10.1016\/j.jcf.2015.02.007_bb0070","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/ppul.1950150204","article-title":"Pulmonary function between 6 and 18years of age","volume":"15","author":"Wang","year":"1993","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2015.02.007_bb0075","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","article-title":"Spirometric reference values from a sample of the general U.S. population","volume":"159","author":"Hankinson","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jcf.2015.02.007_bb0080","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic fibrosis inhaled tobramycin study group","volume":"340","author":"Ramsey","year":"1999","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jcf.2015.02.007_bb0085","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ppul.20097","article-title":"Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease","volume":"38","author":"Murphy","year":"2004","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2015.02.007_bb0090","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jcf.2011.07.003","article-title":"Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint","volume":"10","author":"VanDevanter","year":"2011","journal-title":"J Cyst Fibros"},{"issue":"13","key":"10.1016\/j.jcf.2015.02.007_bb0095","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJM199503303321303","article-title":"Effect of high-dose ibuprofen in patients with cystic fibrosis","volume":"332","author":"Konstan","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2015.02.007_bb0100","series-title":"2012 annual data report to the Center Directors, Bethesda Maryland","author":"Cystic Fibrosis Foundation Patient Registry","year":"2013"},{"issue":"1","key":"10.1016\/j.jcf.2015.02.007_bb0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/1479972311433575","article-title":"Factors associated with a shorter time until the next pulmonary exacerbation in adult patients with cystic fibrosis","volume":"9","author":"Sequeiros","year":"2012","journal-title":"Chron Respir Dis"},{"issue":"1","key":"10.1016\/j.jcf.2015.02.007_bb0110","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1513\/AnnalsATS.201407-338OC","article-title":"Chest CT predicts the frequency of pulmonary exacerbations in children with cystic fibrosis","volume":"12","author":"Sanders","year":"2015","journal-title":"Ann Am Thorac Soc"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199315000478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199315000478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T12:56:17Z","timestamp":1537793777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199315000478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S1569199315000478"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2015.02.007","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2015.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}